

HCM City, January 22, 2025

**TO: State Securities Commission
State Securities Commission Hanoi Stock Exchange**

Based on Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on "Guidelines for Information Disclosure on the Securities Market".

Based on the consolidated financial statements of the fourth quarter of 2024 of Central Pharmaceutical Joint Stock Company Codupha, as disclosed.

Central Pharmaceutical Joint Stock Company Codupha provides the following explanation: Profit after Corporate Income Tax changed by more than 10% on the financial statements of Q4/2024 compared to Q4/2023. (According to Section a, Clause 4, Article 14, Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance)

A/ Separate and consolidated business results report for Q4/2024:

Đvt: VND

No.	Indicator	SEPARATE FINANCIAL STATEMENT			
		Q4.2024	Q4.2023	Amount Discrepancy	Percentage of Increase/ Decrease
	1	2	3	4=(2-3)	5 =4/5
	Profit after Corporate Income Tax	3.784.763.334	3.698.315.238	86.448.096	2,34%

No.	Indicator	CONSOLIDATED FINANCIAL STATEMENT			
		Q4.2024	Q4.2023	Amount Discrepancy	Percentage of Increase/ Decrease
	1	2	3	4=(2-3)	5 =4/5
	Profit after Corporate Income Tax	2.904.218.153	1.685.282.416	1.218.935.737	72,33%

B/ Reasons: The consolidated financial statements have led to a discrepancy in the profit after corporate income tax in Q4/2024 compared to the same period last year for the Company due to:

- Sales service revenue in Q4/2024 was higher than the same period: Increased revenue from Hisamitsu goods, commission goods fees, etc.
- Cost of goods sold in Q4/2024 was higher than the same period, increased due to some high gross profit items.
- Administrative expenses in Q4/2024 decreased compared to the same period as the Company reduced provisions for overdue receivables.

The above is the explanation of Central Pharmaceutical Joint Stock Company Codupha regarding the changes in consolidated business results in Q4/2024 compared to Q4/2023.

Central Pharmaceutical Joint Stock Company Codupha hereby informs the State Securities Commission and the Hanoi Stock Exchange.

Sincerely,

**CODUPHA CENTRAL PHARMACEUTICAL
COMPANY JSC**

GENERAL DIRECTOR



BUI HUU HIEN

